| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2880261 | The Annals of Thoracic Surgery | 2009 | 9 Pages |
Abstract
Progenitor cell therapy is a promising treatment for ischemic heart disease. Early clinical trials of autologous bone marrow-derived progenitor cell therapy for acute and chronic myocardial ischemia showed modest functional improvements after cell delivery; however, the duration of these benefits remains unclear. Ongoing investigations continue to enhance our understanding of the mechanisms by which progenitor and stem cells function and how their survival and cardioprotective abilities can be improved. This review discusses: (1) relevant progenitor and stem cells in myocardial regenerative therapy, (2) routes of cell delivery to ischemic myocardium, (3) clinical trials investigating bone marrow-derived progenitor cell therapy for myocardial ischemia, and (4) future directions of the field.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jeremy L. MD, Aaron M. MD, Brent R. MD, Yue PhD, Meijing MD, Jiangning MD, PhD, Daniel R. MD,